Research
AZD2171 for Central Nervous System Tumors
AZD2171 for Treatment of Recurrent or Progressive Central Nervous System Tumors in Children
Protocol Description
This Phase I study involves an experimental drug called AZD2171, which has been shown to block the formation of new blood vessels that tumor cells need to grow and survive. By inhibiting angiogenesis, this drug may be useful in treating brain or spinal tumors. Researchers will measure the levels of certain cells and proteins in the blood and urine and relate them to how the tumor responds to the drug.
Eligibility Criteria
Patients of both genders up to age 21 who have been diagnosed with a recurrent or progressive brain or spinal cord tumor who have been unable to be cured by any known standard treatment will be asked to participate.
Males: Up to age 21
Females: Up to age 21
Requirements
Eligible patients will be given AZD2171 orally once a day continuously for up to 1 year.
Frequency of visits: Weekly for 6 weeks, then monthly as needed
Duration: Up to 1 year
Status: Open for Enrollment
Sources of Support
Pediatric Brain Tumor Consortium
National Cancer Institute
Additional Resources
Study description at National Institutes of Health
National Cancer Institute
Primary Investigator(s)
Regina Jakacki, MD
Contact Information
To get started, please contact:
Sharon DiBridge, CRA
412-692-7070
Angela Krol, Research RN, BSN
412-692-8047
